A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV

Pain Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg (Hydrocodone 5 mg/Acetaminophen 325 mg/Promethazine 12.5 mg) as a Treatment for Moderate-to-Severe Acute Pain and the Prevention of Opioid-Induced Nausea and Vomiting (OINV) Following Orthopedic Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03657810
• Other study ID #: CLCT-018
• Status: Completed
• Phase: Phase 3
• Start date: August 2, 2017
• Est. completion date: November 30, 2018

Study information

• Verified date: February 2023
• Source: Charleston Laboratories, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine the analgesic efficacy of CL-108 5 mg by comparison with placebo and the anti-emetic efficacy of CL-108 5 mg by comparison with hydrocodone 5 mg/acetaminophen 325 mg.

Description:

Adult patients with moderate or severe pain after bunionectomy will be randomized to CL-108 5 mg (hydrocodone 5 mg/acetaminophen 325 mg/ promethazine 12.5 mg), hydrocodone 5 mg/ acetaminophen 325 mg, or placebo under double-blind conditions. Over 48 hours they will use the assigned study medication and assess pain intensity, nausea, and vomiting. Uses of supplementary analgesic and antiemetic medications will be documented. Patient responses and adverse effects will also be documented during the 5-day outpatient period, too.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 349
• Est. completion date: November 30, 2018
• Est. primary completion date: April 16, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Informed consent: Signed informed consent form obtained at screening prior to any procedures being performed.
• Gender: Male or non-pregnant and non-lactating female.
• Age: 18 years or older at time of consent.
• Foot condition: Primary unilateral first metatarsal bunionectomy (osteotomy and internal fixation) with no additional collateral procedures.
• Pain Severity: Presence of moderate or severe pain on a categorical pain intensity scale at Baseline
• Pain Confirmation: On the 0-10 numerical pain intensity scale at Baseline.
• Diary Completion: Be willing and able to record safety and efficacy ratings in the Diaries.
• Safe Transportation Home: Patient must have arrangements for transportation home from the research center accompanied by a responsible adult.

Exclusion Criteria:

• Medical condition: Presence of a serious medical condition, intolerance to NSAIDs, or any other medical condition which, in the opinion of the Investigator, makes the patient unsuitable for participation.
• Infection: Acute infection of the surgical site at the time of surgery that could confound post-surgical evaluation.
• Drug Allergy: History of hypersensitivity to an opioid drug (such as hydrocodone), promethazine, acetaminophen, NSAID (such as ibuprofen or aspirin), midazolam, propofol, mepivacaine, ropivacaine or ketorolac.
• Confounding and Contraindicated Drugs: Other than protocol-permitted medications administered pre-operatively or during surgery: use within 14 days before or during the surgical procedure of any systemic corticosteroid or use within 24 hours or during the surgical procedure of any confounding prescription or non-prescription drug or any drug contraindicated with hydrocodone, acetaminophen, or promethazine. [Note: Antibiotic for endocarditis prophylaxis (except if known to cause nausea) and aspirin (ASA) = 325 mg for cardiovascular prophylaxis are permitted during the study.] History of consuming more than 2 alcoholic drinks per day every day for the last month or a positive urine test for opiates, benzodiazepines, barbiturates, tetrahydrocannabinol, methamphetamines, cocaine, oxycodone, cotinine at screening or the morning of surgery will exclude the patient from the trial.
• Investigational Drug Use: Use of an investigational drug within the past 30 days.
• Participated in Study: Previous participation in this study.
• Pregnancy, Lactation: Women who are pregnant or lactating.
• Compliance: Inability to swallow capsules whole.
• Participant relationship: Employee at the research center, employee of the Principal Investigator, Sub-Investigators, or sponsor or relative of the Investigator, Sub-Investigators or research staff who is involved in this study.

Related Conditions & MeSH terms

• Acute Pain
• Nausea
• Pain
• Vomiting

Intervention

Drug:
• CL-108 5 mg
hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg
• Norco
hydrocodone 5 mg/APAP 325 mg
• Placebo
Placebo matching CL-108

Locations

Country	Name	City	State
United States	Optimal Research	Austin	Texas
United States	Chesapeake	Pasadena	Maryland
United States	Arizona Research Center	Phoenix	Arizona
United States	Jean Brown Research	Salt Lake City	Utah
United States	Endeavor Clinical Research	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Charleston Laboratories, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With OINV Over 48 Hours	Number and Percentage of participants With opioid-induced nausea and vomiting (OINV) who experienced any Vomiting / use of Anti-Emetic Medication Over 48 Hours	Up to 48 hours
Primary	The Sum of Pain Intensity Differences (on PI-NRS) Over 48 Hours (SPID48)	The SPID48 endpoint is calculated from the PI-NRS values at baseline, every 30 minutes until hour 12, then every hour (when awake) until hour 48 as follows: Each subsequent PI-NRS value is subtracted from the baseline PI-NRS value.; Each difference is weighted by the elapsed time from the previous PI-NRS value to the current one.; The weighed differences are summed to yield the SPID48.; Summed pain intensity differences over 48 hours (SPID48) will be compared for patients treated with CL-108 5 mg and those treated with placebo. Pain intensity will be measured on a 0-10 Pain Intensity Numerical Rating Scale (PI-NRS), where 0 is "no pain" and 10 is "severe pain".	Up to 48 hours
Secondary	Percentage of Patients With Complete Absence of OINV (no Nausea, no Vomiting, and no Use of Anti-emetic Medication) Over 48 Hours	Percentage of patients with complete absence of OINV (no nausea, no vomiting, and no use of anti-emetic medication) over 48 hours comparing CL-108 5 mg to hydrocodone 5 mg/APAP 325 mg)	Up to 48 hours
Secondary	Percentage of Patients With Any Vomiting Over 48 Hours	Percentage of patients with any vomiting over 48 hours, comparing CL-108 5 mg to hydrocodone 5 mg/APAP 325 mg	Up to 48 hours
Secondary	Percentage of Patients With Any Nausea Over 48 Hours	Percentage of patients with any nausea over 48 hours, comparing CL-108 5 mg to hydrocodone 5 mg/APAP 325 mg	Up to 48 hours
Secondary	Percentage of Patients With Any Nausea or Vomiting Over 48 Hours	Percentage of patients with any nausea or vomiting over 48 hours, comparing CL-108 5 mg to hydrocodone 5 mg/APAP 325 mg	Up to 48 hours
Secondary	Percentage of Patients With Any Post-discharge Nausea and Vomiting (PDNV)	Percentage of patients with any Post-discharge Nausea and Vomiting (PDNV) over Days 3 to 7	Day 3 to 7
Secondary	Number of Doses of Study Medication Taken Over Days 3to7	Number of doses of study medication taken over Days 3 to 7	Day3 to Day7
Secondary	Number of Doses of Study Medication Taken Per Day Over Days 3to7	Number of doses of study medication taken per day over Days 3 to 7	Day3 to Day7

External Links

•   Charleston Website